Drug Patents owned by Sanofi Aventis Us
1. List of Aubagio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6794410 | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(3 years from now) | |
|
US6794410
(Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(4 years from now) | |
| US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(7 years from now) | |
|
US8802735
(Pediatric) | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(8 years from now) | |
| US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(10 years from now) | |
|
US9186346
(Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Apr 30, 2024 |
| Pediatric Exclusivity (PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose
Dosage: TABLET;ORAL
AUBAGIO family patents
17
United States
6
European Union
4
China
3
Israel
3
Peru
2
Hong Kong
2
Australia
2
Chile
2
Ukraine
2
Uruguay
2
Spain
2
Cyprus
2
Slovenia
2
Argentina
2
Portugal
2
Russia
2
New Zealand
2
Honduras
2
Canada
2
Taiwan, Province of China
2
Denmark
2
Costa Rica
1
Austria
1
Morocco
1
RS
1
Korea, Republic of
1
Brazil
1
Poland
1
Lithuania
1
Malaysia
1
Luxembourg
1
Guatemala
1
Dominican Republic
1
Jordan
1
Germany
1
Mexico
1
Japan
1
Tunisia
1
Hungary
1
Ecuador
1
United Kingdom
1
Colombia
1
Belgium
1
Croatia
1
ME
1
Panama
1
Nicaragua
2. List of Jevtana Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7241907 | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Dec, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7241907
(Pediatric) | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Jun, 2026
(3 years from now) | |
| US10583110 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(7 years from now) | |
| US8927592 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(7 years from now) | |
| US10716777 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(7 years from now) | |
|
US8927592
(Pediatric) | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Apr, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Dec 18, 2023 |
Drugs and Companies using CABAZITAXEL ingredient
Market Authorisation Date: 17 June, 2010
Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist; Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist
Dosage: SOLUTION;INTRAVENOUS
JEVTANA KIT family patents
16
United States
6
Australia
5
New Zealand
4
China
3
Japan
3
Canada
3
Taiwan, Province of China
2
Morocco
2
Korea, Republic of
2
Brazil
2
Poland
2
Malaysia
2
Ukraine
2
Spain
2
Israel
2
Mexico
2
Tunisia
2
Argentina
2
South Africa
2
Portugal
2
Peru
2
ME
2
Norway
2
France
2
Denmark
2
Costa Rica
2
European Union
1
Hong Kong
1
RS
1
Chile
1
Guatemala
1
Luxembourg
1
Dominican Republic
1
Yugoslavia
1
Uruguay
1
Cyprus
1
Slovenia
1
IB
1
Hungary
1
El Salvador
1
Colombia
1
Singapore
1
Russia
1
EA
1
Croatia
1
Nicaragua
1
Panama
1
Ecuador
3. List of Multaq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9107900 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
Apr, 2029
(6 years from now) | |
| US8410167 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Apr, 2029
(6 years from now) | |
| US8602215 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
Jun, 2031
(8 years from now) | |
Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient
Market Authorisation Date: 01 July, 2009
Treatment: Reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; Reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af
Dosage: TABLET;ORAL
MULTAQ family patents
19
United States
8
European Union
3
France
3
Taiwan, Province of China
2
Morocco
2
Korea, Republic of
2
Brazil
2
Australia
2
Chile
2
Dominican Republic
2
Uruguay
2
Mexico
2
Japan
2
IB
2
Ecuador
2
South Africa
2
Argentina
2
El Salvador
2
Colombia
2
Peru
2
EA
2
China
2
Canada
2
Costa Rica
2
Nicaragua
1
Malaysia
1
Ukraine
1
Tunisia
1
New Zealand
4. List of Oforta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7148207 | SANOFI AVENTIS US | Oral fludara of high-purity formulation with quick release of active ingredient |
Dec, 2022
(a month ago) | |
Drugs and Companies using FLUDARABINE PHOSPHATE ingredient
Market Authorisation Date: 18 December, 2008
Treatment: Treatment of patients with b-cell chronic lymphocytic leukemia (cll)
Dosage: TABLET;ORAL
OFORTA family patents
2
Germany
2
Japan
2
United States
2
European Union
1
Austria
1
Hong Kong
1
Korea, Republic of
1
Brazil
1
Australia
1
Poland
1
Saudi Arabia
1
Ukraine
1
Yugoslavia
1
Uruguay
1
Jordan
1
Spain
1
Israel
1
Mexico
1
South Africa
1
Argentina
1
Peru
1
Russia
1
Croatia
1
China
1
Norway
1
Canada
1
New Zealand
1
Taiwan, Province of China
1
Denmark
1
Ecuador
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic